<p>At GSK, our fundamental purpose is to apply scientific and technological innovation to address the world's most significant health challenges. Our focus remains on delivering meaningful advancements that improve the lives of patients globally, driven by substantial investment in research and development and strategic partnerships.</p><p>We are particularly encouraged by the progress in our pipeline, with five new medicines and vaccines anticipated for approval this year. These are part of a broader cohort of 14 potential medicines and vaccines expected to launch this decade, each designed to make a significant difference for patients on a wide scale. This includes work across oncology, infectious diseases, respiratory conditions, immunology, and HIV.</p><p>Breakthroughs are emerging from new technology platforms. For instance, in multiple myeloma, a severe blood cancer affecting 180,000 new patients annually, we are developing an antibody-drug conjugate. This platform acts like a pr...
<p>At GSK, our fundamental purpose is to apply scientific and technological innovation to address the world's most significant health challenges. Our focus remains on delivering meaningful advancements that improve the lives of patients globally, driven by substantial investment in research and development and strategic partnerships.</p><p>We are particularly encouraged by the progress in our pipeline, with five new medicines and vaccines anticipated for approval this year. These are part of a broader cohort of 14 potential medicines and vaccines expected to launch this decade, each designed to make a significant difference for patients on a wide scale. This includes work across oncology, infectious diseases, respiratory conditions, immunology, and HIV.</p><p>Breakthroughs are emerging from new technology platforms. For instance, in multiple myeloma, a severe blood cancer affecting 180,000 new patients annually, we are developing an antibody-drug conjugate. This platform acts like a precise biological targeting system, aiming to deliver greater efficacy with fewer side effects. Early data for a new multiple myeloma drug suggests it could extend life expectancy by three years, a profound improvement for patients facing this diagnosis. Similarly, in the field of oligonucleotides, which act to correct disease development at the genetic level, we are exploring a potential functional cure for hepatitis B, a condition that impacts 250 million people worldwide.</p><p>Our commitment extends to both prevention and early intervention. Vaccines remain a powerful tool to protect against disease before it takes hold, representing one of the most effective returns on investment in public health. We are also looking at the long-term horizon, including the exciting potential of cancer vaccines. In treatment, our focus is on earlier interventions that can alter the course of disease and reduce the need for hospitalization. Long-acting medicines in development for HIV and respiratory conditions aim to help patients manage their health more effectively and maintain their quality of life outside of clinical settings.</p><p>Beyond specific innovations, our efforts address widespread health burdens. Our respiratory medicines, including treatments for conditions like chronic obstructive pulmonary disease (COPD), tackle a disease that is the third leading cause of death globally,</p>